Jefferies London 2026: CRISPR Therapeutics CEO Sam Kulkarni walks us through the company's increasingly advancing pipeline, which includes an siRNA
Jefferies London 2026: CRISPR Therapeutics CEO Sam Kulkarni walks us through the company's increasingly advancing pipeline, which includes an siRNA
重點導讀
He discusses ANGPTL3 in cardiology and allo CAR-T, both of which recently had data at medical meedings. Plus the idea behind branching out to siRNA, which targets FXI for thrombotic conditions.
AI 伴隨問答
針對這篇報導有疑問?可直接點選快捷問題或向 AI 追問背景脈絡與技術細節:
Podcast 專家音訊節目
收錄於 888news Podcast 智庫專區,包含精華摘要與上市公司即時行情
正文
He discusses ANGPTL3 in cardiology and allo CAR-T, both of which recently had data at medical meedings. Plus the idea behind branching out to siRNA, which targets FXI for thrombotic conditions.
來源: BiotechTV - News (podcasters.spotify.com)
開啟原文